08:08 AM EDT, 10/25/2024 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) , which is advancing new anti-cancer therapeutics based on DNA-damage response technologies, on Friday announced the presentation of its research on novel small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes at a symposium in Barcelona, Spain.

The company's class of compounds, known as the kt-3000 series, has demonstrated "potent" dual inhibition of PARP1/2 and HDAC enzymes in preclinical studies. Rakovina intends to explore formulations of the lead compound, kt-3283, to support potential advancement to human clinical trials.

"The kt-3000 series represents a significant advancement toward overcoming treatment resistance to first-generation PARP-inhibitors. These bifunctional PARP+HDAC inhibitors could enable us to effectively address resistance in various cancers while minimizing toxicity associated with traditional combination therapies," said Executive Chairman Jeffrey Bacha.